These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 3903584)

  • 1. Subrenal capsule assay as a predictor of clinical response of ovarian cancer to chemotherapy: Part II.
    Mäenpää J
    Obstet Gynecol; 1985 Nov; 66(5):714-8. PubMed ID: 3903584
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response of ovarian cancer to combined cytotoxic agents in the subrenal capsule assay: Part I.
    Mäenpää J; Kangas L; Grönroos M
    Obstet Gynecol; 1985 Nov; 66(5):708-13. PubMed ID: 3932908
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro drug testing of ovarian cancer using the human tumor colony-forming assay: comparison of in vitro response and clinical outcome.
    Federico M; Alberts DS; Garcia DJ; Emerson J; Fanta P; Liu R; Salmon SE
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S156-63. PubMed ID: 7835801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cisplatin sensitivity of ovarian cancer in the histoculture drug response assay correlates to clinical response to combination chemotherapy with cisplatin, doxorubicin and cyclophosphamide.
    Ohie S; Udagawa Y; Kozu A; Komuro Y; Aoki D; Nozawa S; Moossa AR; Hoffman RM
    Anticancer Res; 2000; 20(3B):2049-54. PubMed ID: 10928150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-dose topotecan, melphalan, and cyclophosphamide (TMC) with stem cell support: a new regimen for the treatment of advanced ovarian cancer.
    Donato ML; Gershenson DM; Wharton JT; Ippoliti CM; Aleman AS; Bodurka-Bevers D; Bevers MW; Burke TW; Levenback CF; Wolf JK; Freedman RS; Bast RC; Gajewski JL; Champlin RE
    Gynecol Oncol; 2001 Sep; 82(3):420-6. PubMed ID: 11520135
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cisplatin-based chemotherapy in advanced ovarian cancer: initial experience in an Indian set-up.
    Charak BS; Agarwala S; Gopal R; Advani SH; Nadkarni KS; Pai VR; Saikia TK; Desai PB
    Indian J Cancer; 1989 Jun; 26(2):85-91. PubMed ID: 2592001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
    Thigpen T; Vance R; Puneky L; Khansur T
    Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Clinical application of subrenal capsule assay in ovarian cancer].
    Maeda K; Ushijima H; Shimamoto T; Shigematsu T; Kurano A; Watanabe Y; Jimi S; Okadome M; Mashiba H
    Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):1896-902. PubMed ID: 2592813
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between extreme drug resistance assay and response to primary paclitaxel and cisplatin in patients with epithelial ovarian cancer.
    Eltabbakh GH; Piver MS; Hempling RE; Recio FO; Lele SB; Marchetti DL; Baker TR; Blumenson LE
    Gynecol Oncol; 1998 Sep; 70(3):392-7. PubMed ID: 9790793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subrenal capsule assay in choosing cytostatics for gynaecological tumours.
    Mäenpää J; Grönroos M; Kangas L
    Ann Chir Gynaecol Suppl; 1985; 199():28-30. PubMed ID: 3864390
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
    Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
    Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase II trial of combination intraperitoneal cisplatin and 5-fluorouracil in previously treated patients with advanced ovarian cancer: long-term follow-up.
    Morgan RJ; Braly P; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Najera L; Johnson D; Doroshow JH
    Gynecol Oncol; 2000 Jun; 77(3):433-8. PubMed ID: 10831355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Application of ATP-tumor chemosensitivity assay in primary epithelial ovarian cancer].
    Zhao D; Wu LY; Wang XB; Li XG; Li M; Li YF; Tian HM; Zhang W
    Zhonghua Zhong Liu Za Zhi; 2010 May; 32(5):368-72. PubMed ID: 20723436
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antitumour effect of interferons, cytostatic drugs and their combinations in subrenal capsule assay (SRCA).
    Kangas L; Cantell K; Grönroos M; Mäenpää J; Perilä M
    Ann Chir Gynaecol Suppl; 1985; 199():60-3. PubMed ID: 2415035
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
    Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
    Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 4'-epi-doxorubicin in combination with cisplatin in advanced ovarian cancer.
    Martoni A; Tomasi L; Farabegoli G; Fruet F; Pannuti F
    Cancer Treat Rep; 1984 Nov; 68(11):1391-3. PubMed ID: 6594196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Paclitaxel and cisplatin combination chemotherapy in recurrent epithelial ovarian cancer.
    Goldberg JM; Piver MS; Hempling RE; Recio FO
    Gynecol Oncol; 1996 Dec; 63(3):312-7. PubMed ID: 8946864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
    Wadler S; Yeap B; Vogl S; Carbone P
    Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase II evaluation of tirapazamine plus cisplatin in the treatment of recurrent platinum-sensitive ovarian or primary peritoneal cancer: a Gynecologic Oncology Group study.
    Covens A; Blessing J; Bender D; Mannel R; Morgan M;
    Gynecol Oncol; 2006 Mar; 100(3):586-90. PubMed ID: 16249022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Chemotherapy with paclitaxel, ifosfamide, and cisplatin for the treatment of squamous cell cervical cancer: the experience of Monza.
    Zanetta G; Fei F; Mangioni C
    Semin Oncol; 2000 Feb; 27(1 Suppl 1):23-7. PubMed ID: 10697040
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.